Comparative Pharmacology
Head-to-head clinical analysis: EVISTA versus SOLTAMOX.
Peer-Reviewed Evidence
Head-to-head clinical analysis: EVISTA versus SOLTAMOX.
EVISTA vs SOLTAMOX
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Selective estrogen receptor modulator (SERM) that binds to estrogen receptors, acting as an agonist in bone and antagonist in breast and uterine tissues.
Selective estrogen receptor modulator (SERM). Binds to estrogen receptors, competitively inhibiting estrogen binding. In breast tissue, acts as an antagonist; in bone and cardiovascular system, acts as an agonist.
60 mg orally once daily.
300 mg orally once daily for 5 days, starting on day 1 of menses.
None Documented
None Documented
Terminal elimination half-life is approximately 32.5 hours (range 27-39 hours) for raloxifene and its glucuronide conjugates; clinically relevant for once-daily dosing.
24-36 hours in adults; prolonged in renal impairment (up to 96 hours in ESRD). Steady-state reached in ~5 days.
Raloxifene undergoes extensive glucuronidation; <0.1% excreted unchanged in urine. Approximately 95% is excreted in feces over 5 days (primarily as glucuronide conjugates). Renal elimination of unchanged drug is negligible (<0.1%).
Primarily renal (80-90% as unchanged drug); biliary/fecal excretion accounts for 10-20%.
Category C
Category C
Selective Estrogen Receptor Modulator
Selective Estrogen Receptor Modulator